Full Press Release Details
CAMBRIDGE, Mass., April 15, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present two posters, including a late-breaker with data from its lead immunoconjugate candidate, at the American Association for Cancer Research (AACR) Annual Meeting taking place April 18-22 at the Pennsylvania Convention Center in Philadelphia, PA.
The poster details are as follows:
| Title: Trastuzumab-dolaflexin, a highly potent Fleximer-based antibody-drug conjugate, demonstrates a favorable therapeutic index in exploratory toxicology studies in multiple species |
| Abstract Number: 641 |
| Date: Sunday, April 19, 2015 |
| Time: 1:00 p.m. - 5:00 p.m. ET |
| Presenter: Natasha Natalya Bodyak, Ph.D., Senior Director, Biology, Mersana |
| Late-Breaker Title: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors |
| Abstract Number: LB-231 |
| Date: Tuesday, April 21, 2015 |
| Time: 1:00 p.m. - 5:00 p.m. ET |
| Presenter: Donald A. Bergstrom, M.D., Ph.D., Chief Medical Officer, Mersana |
In addition, Asana BioSciences will present data developed in collaboration with Mersana.
The poster details are as follows:
| Title: ASN004, a novel 5T4-targeted Dolaflexin antibody drug conjugate, causes complete regression in multiple solid tumor models |
| Abstract Number : 1693 |
| Date: Monday, Apr 20, 2015 |
| Time: 8:00 a.m. - 12:00 p.m. |
| Presenter: Roger A. Smith, Ph.D., Vice President, Asana BioSciences |
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences.